All Releases
 |
Vical to Present at Canaccord Genuity Growth Conference
Aug 4, 2010
|
7.8 KB |
| |
SAN DIEGO, Aug. 4, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies and development programs at the Canaccord Genuity 30th Annual Growth Conference (Boston, August 10 – 12).
A webcast of Mr. S...
|
|
Vical Reports Second Quarter 2010 Financial Results and Progress in Key Programs
Aug 3, 2010
|
17.3 KB |
| |
SAN DIEGO, Aug. 3, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 ...
|
|
Vical Announces News Release and Conference Call Schedule for Second Quarter 2010 Financial Results
Jul 27, 2010
|
9.4 KB |
| |
SAN DIEGO, July 27, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and six months ended June 30, 2010, before the opening of trading on Tuesday, August 3, and conduct a conference call and webcast to discuss the financial results and provide a company up...
|
|
Vical's Herpes Simplex Vaccines Protect Against Lethal Challenge and Demonstrate Significant Therapeutic Benefit in Animal Models
Jul 26, 2010
|
11.6 KB |
| |
SAN DIEGO, July 26, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that its prophylactic Vaxfectin®-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection s...
|
|
Vical's Allovectin-7(R) Phase 3 Trial Receives Positive Review From Safety Monitoring Board
Jun 16, 2010
|
9.9 KB |
| |
SAN DIEGO, June 16, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fourth scheduled safety analysis and recommended that the trial continue per the protocol.
...
|
|
Vical to Present at Two Upcoming Investor Conferences
Jun 7, 2010
|
8.2 KB |
| |
SAN DIEGO, June 7, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at two upcoming investor conferences:· Ninth Annual Needham Life Sciences Co...
|
|
Vical to Present at Three Upcoming Investor Conferences
Jun 1, 2010
|
8.3 KB |
| |
SAN DIEGO, June 1, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at three upcoming investor conferences:
Noble Financial Group Sixth Annua...
|
|
Vical Collaborators Receive Grant to Pursue Novel CMV Vaccine Strategies
May 25, 2010
|
12.0 KB |
| |
SAN DIEGO, May 25, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company is collaborating with leading pediatric infectious disease researchers Stuart P. Adler, M.D., and Michael A. McVoy, Ph.D., of Virginia Commonwealth University (VCU) under a five-year, approximately $4.0 million grant from the National Inst...
|
|
Vical to Close NASDAQ Stock Market
May 24, 2010
|
8.1 KB |
| |
NEW YORK, May 24, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will preside over The NASDAQ Stock Market Closing Bell ceremony from 3:50 p.m. to 4:05 p.m. EDT on Tuesday, May 25. The event will be accessible via live webcast at www.nasdaq.com/a...
|
|
Allovectin-7(R) Achieves Median Survival of Nearly 19 Months in Phase 2 Melanoma Trial
May 12, 2010
|
12.1 KB |
| |
SAN DIEGO, May 12, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced the publication in the June issue of Melanoma Research[1] of updated data from the company's Phase 2 trial of high-dose (2 mg) Allovectin-7® in patients with metastatic melanoma. A separate article in the May issue of Expert Opinion on Biological Therapy[2] revi...
|
|
Vical to Present at Rodman & Renshaw Global Healthcare Conference
May 11, 2010
|
8.0 KB |
| |
LONDON, May 11, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and outlook on Monday, May 17, at the Rodman & Renshaw 6th Annual Global Healthcare Conference (London, Ma...
|
|
Vical Reports First Quarter 2010 Financial Results and Progress in Key Programs
May 6, 2010
|
15.4 KB |
| |
SAN DIEGO, May 6, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Ope...
|
|
Vical Begins Phase 1 Trial of DNA Vaccine Against H1N1 Pandemic Influenza
May 5, 2010
|
8.7 KB |
| |
SAN DIEGO, May 5, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin®-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center (NMRC).
"The H1N1 outbr...
|
|
Vical CEO Selected as Panelist at BIO and PGH Conferences
Apr 30, 2010
|
8.5 KB |
| |
CHICAGO, April 30, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will participate as a panelist at two upcoming conferences.
On Monday, May 3, at 2:00 p.m. CDT, Mr. Samant will participate in the panel discussion, "Inside the Boardroom: Indust...
|
|
Vical Announces News Release and Conference Call Schedule for First Quarter 2010 Financial Results
Apr 29, 2010
|
9.2 KB |
| |
SAN DIEGO, April 29, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2010, before the opening of trading on Thursday, May 6, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Ea...
|
|
Vical Reports Encouraging Updates From U.S. Military Malaria Vaccine Programs
Apr 27, 2010
|
10.2 KB |
| |
SAN DIEGO, April 27, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that a prime-boost malaria vaccine regimen provided sterile protection, with no disease symptoms and no detectable malaria parasites, in 4 of 15 vaccinated volunteers a full 28 days after challenge with multiple infected-mosquito bites. The remaining 11 ...
|
|
Vical Presents Encouraging Preliminary Data From Final 12-month Follow-up in TransVax(TM) CMV Vaccine Phase 2 Transplant Recipient Trial
Apr 22, 2010
|
9.5 KB |
| |
SAN DIEGO, April 22, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's TransVax™ cytomegalovirus (CMV) vaccine elicited sustained increases in both cellular and antibody immune responses compared with placebo through the final 12-month follow-up in an ongoing Phase 2 trial in hematopoietic cell transplant...
|
|
Vical Secures Funding to Proceed With Phase 1 Trial of H1N1 Pandemic Influenza Vaccine
Mar 22, 2010
|
10.8 KB |
| |
SAN DIEGO, March 22, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the U.S. Navy, through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., has awarded Vical a contract to conduct a Phase 1 clinical trial of the company's Vaxfectin®-formulated DNA vaccine against A/H1N1 pandemic influe...
|
|
Vical to Present at Upcoming Investor Conferences
Mar 1, 2010
|
8.3 KB |
| |
SAN DIEGO, March 1, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of the company's technologies, development programs, and outlook at two upcoming investor conferences.
Vical's President and Chief Executive Officer, Vijay B. Samant, will present on Monday, March 8, at 4:00 p....
|
|
Publication of Vical's H5N1 Results Paves the Way for H1N1 Clinical Trial
Feb 24, 2010
|
10.8 KB |
| |
SAN DIEGO, Feb. 24, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the publication in the online edition of Vaccine1 detailed data from two Phase 1 trials of the company's Vaxfectin®-adjuvanted DNA vaccines for H5N1 (avian-origin) influenza, demonstrating the potential of DNA vaccines for rapid deployment in future pande...
|
|
Vical Reports 2009 Financial Results and Progress in Key Development Programs
Feb 11, 2010
|
17.7 KB |
| |
SAN DIEGO, Feb. 11, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2009. Vical had cash and investments of approximately $53 million at year-end 2009. The company raised approximately $33 million of net proceeds from the sale of equity securities during 2009, and approxima...
|
|
Vical Announces News Release and Conference Call Schedule for 2009 Financial Results
Feb 4, 2010
|
9.3 KB |
| |
SAN DIEGO, Feb. 4, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and twelve months ended December 31, 2009, before the opening of trading on Thursday, February 11, and conduct a conference call and webcast to discuss the financial results and provide a ...
|
|
Vical Completes Enrollment in Allovectin-7(r) Phase 3 Trial for Metastatic Melanoma
Jan 28, 2010
|
13.6 KB |
| |
SAN DIEGO, Jan. 28, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company has completed enrollment of the planned 375 subjects in its multinational Phase 3 trial of Allovectin-7® in patients with metastatic melanoma. Allovectin-7® is a novel gene-based immunotherapeutic with a unique mechanism of action that is ...
|
|
Vical Updates Vaccine Development Programs for CMV and Pandemic Influenza
Jan 26, 2010
|
8.0 KB |
| |
WASHINGTON, Jan. 26, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present an overview of its DNA vaccine and adjuvant technologies and an update on its clinical-stage vaccine development programs at the Phacilitate Vaccine Forum (Washington - January 25-27). Alain P. Rolland, Pharm.D., Ph.D., Vical...
|
|
Vical Names Richard T. Kenney, M.D., Vice President of Clinical Development
Jan 14, 2010
|
8.7 KB |
| |
SAN DIEGO, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the appointment of Richard T. Kenney, M.D., as Vice President, Clinical Development.
Prior to joining Vical, Dr. Kenney held key positions in influenza and biodefense vaccine development at GSK Biologicals (formerly ID Biomedical) from 2005 to 2009, mos...
|
|
Vical Licensee AnGes MG Reaches Agreement With FDA For Phase 3 Trial of Collategene(TM) Angiogenesis Product
Jan 12, 2010
|
9.7 KB |
| |
SAN DIEGO, Jan. 12, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's licensee, AnGes MG, Inc., reported approval by the U.S. Food and Drug Administration (FDA) of the Special Protocol Assessment (SPA) agreement for a Phase 3 clinical trial of its Collategene(TM) angiogenesis product for patients with adva...
|
|
Vical Announces Licensee's Approval of ONCEPT(TM) Therapeutic Melanoma Vaccine for Dogs
Jan 11, 2010
|
10.5 KB |
| |
SAN DIEGO, Jan. 11, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the U.S. Department of Agriculture (USDA) has granted the company's licensee Merial Limited, the animal health subsidiary of sanofi-aventis, full licensure for its ONCEPT(TM) canine melanoma vaccine, a therapeutic DNA vaccine designed to aid in extend...
|
|
Vical Secures $25 Million Issuer Managed Equity Facility With Azimuth Opportunity, Ltd.
Jan 8, 2010
|
7.9 KB |
| |
SAN DIEGO, Jan. 8, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has secured an issuer managed equity facility under which it may sell up to $25 million of its registered common stock to Azimuth Opportunity, Ltd. Vical is not obligated to use any of the facility.
From time to time during the 24-month term of t...
|
|
Mechanism of Action for Vical's Vaxfectin(R) Adjuvant Expands Potential Applications
Jan 7, 2010
|
9.7 KB |
| |
SAN DIEGO, Jan. 7, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that systematic in vivo testing of the company's Vaxfectin(R) adjuvant shows that it increased antibody and T-cell responses primarily by stimulating the immune system rather than simply increasing vaccine uptake. The results, published in the journal Vacci...
|
|
Vical Confirms Advantages of DNA Technology Platform With Vaccine for H1N1 Influenza
Dec 29, 2009
|
10.8 KB |
| |
SAN DIEGO, Dec. 29, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the publication of data documenting the successful pilot lot production and initiation of animal immunogenicity testing of a Vaxfectin(R)-adjuvanted DNA vaccine for H1N1 influenza before conventional vaccine manufacturers even received the seed virus neede...
|
|
Vical's Allovectin-7(R) Phase 3 Trial Receives Positive Review From Safety Monitoring Board
Dec 28, 2009
|
11.1 KB |
| |
SAN DIEGO, Dec. 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 AIMM trial of Allovectin-7(R) in patients with metastatic melanoma has completed the trial's third scheduled safety analysis and recommended that the trial continue per the protoco...
|
|
Vical and the University of Washington Receive U.S. Patent for Herpes Simplex DNA Vaccine
Dec 22, 2009
|
10.8 KB |
| |
SAN DIEGO, Dec. 22, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,628,993 covering DNA vaccines for herpes simplex virus type 2 (HSV-2). HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes. Vical is collaborating under a previously disclosed grant(1) on the...
|
|
Vical Advocates DNA Vaccine Approach With Pandemic Influenza Experts
Dec 9, 2009
|
9.5 KB |
| |
BRUSSELS, Belgium, Dec. 9, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company is addressing an international gathering of pandemic influenza vaccine experts and potential commercial partners to encourage broader use of the company's DNA vaccine technology and Vaxfectin(R) adjuvant. Larry R. Smith, Ph.D., Vica...
|
|
Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial
Nov 23, 2009
|
8.8 KB |
| |
SAN DIEGO, Nov. 23, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company has completed the last scheduled follow-up visit for the final patient enrolled in a Phase 2 trial of its TransVax(TM) cytomegalovirus (CMV) vaccine in hematopoietic stem cell transplant (HCT) recipients. The company expects to have data a...
|
|
Vical Added to NASDAQ Biotechnology Index
Nov 16, 2009
|
9.9 KB |
| |
SAN DIEGO, Nov. 16, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will be added to the NASDAQ Biotechnology Index effective with the U.S. market open on Monday, November 23, 2009.
"We are pleased that Vical has been selected as a member of the NASDAQ Biotechnology Index," said Vical's Senior Vice Pres...
|
|
Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases
Nov 10, 2009
|
7.9 KB |
| |
GALVESTON, Texas, Nov. 10, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today is presenting a strong rationale advocating the use of DNA vaccine technology for emerging and/or pandemic infectious diseases. At the University of Texas Medical Branch Symposium, "The Changing Landscape of Vaccine Development," Larry R. Smith, Ph.D., the co...
|
|
Vical Reports Third Quarter 2009 Financial Results and Progress in Key Development Programs
Nov 4, 2009
|
16.4 KB |
| |
SAN DIEGO, Nov. 4, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the quarter ended September 30, 2009. Revenues for the third quarter of 2009 increased to $3.9 million, compared with revenues of $0.8 million for the third quarter of 2008, primarily as a result of increased revenue from AnGes MG, Inc....
|
|
Vical Announces News Release and Conference Call Schedule for Third Quarter 2009 Financial Results
Oct 28, 2009
|
7.6 KB |
| |
SAN DIEGO, Oct. 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and nine months ended September 30, 2009, before the opening of trading on Wednesday, November 4, and conduct a conference call and webcast to discuss the financial results and provide a c...
|
|
Vical to Present at BIOCOM Investor Conference
Oct 27, 2009
|
6.7 KB |
| |
SAN DIEGO, Oct. 27, 2009 (GLOBE NEWSWIRE) -- Jill M. Broadfoot, Senior Vice President and Chief Financial Officer of Vical Incorporated (Nasdaq:VICL), will be presenting an overview of the company's independent and collaborative development programs at the BIOCOM Investor Conference in San Diego today, Tuesday, October 27.
About Vical
Vical r...
|
|
Vical's Vaxfectin® Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi-Pasteur Fluzone® Seasonal Influenza Vaccine
Oct 26, 2009
|
9.6 KB |
| |
SAN DIEGO, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the publication of two articles regarding the company's Vaxfectin® adjuvant in a special issue of Vaccine.(1,2) One article highlighted preclinical data showing Vaxfectin®'s improv...
|
|
Vical's TransVax(TM) CMV Vaccine Elicits Long-Term Immune Responses in Phase 2 Trial
Oct 7, 2009
|
8.0 KB |
| |
SAN DIEGO, Oct. 7, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's TransVax(TM) cytomegalovirus (CMV) vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial. Alain P. Rolland, Pharm.D...
|
|
U.S. Navy to Fund Vical's H1N1 Pandemic Influenza (Swine Flu) Vaccine
Oct 1, 2009
|
7.9 KB |
| |
SAN DIEGO, Oct. 1, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the U.S. Navy has awarded a contract for $1.25 million to support large-scale cGMP vaccine manufacturing and related clinical and regulatory preparations, which are already underway, for a Phase 1 clinical trial of the company's vaccine against A/H1N1 ...
|
|
Vical Licensee Sanofi-aventis Completes Enrollment in Phase 3 Angiogenesis Trial
Sep 28, 2009
|
8.7 KB |
| |
SAN DIEGO, Sept. 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's licensee, sanofi-aventis, has confirmed the completion of enrollment in a multinational 500-patient pivotal Phase 3 clinical trial of its angiogenesis therapy based on Vical's non-viral DNA delivery technology. Sanofi-aventis expects fi...
|
|
Vical Presents Positive Preclinical Results with Vaxfectin(R)-Formulated, Peptide-based Cancer Vaccine
Sep 24, 2009
|
9.3 KB |
| |
BOSTON, Sept. 24, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the presentation of encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company's Vaxfectin(R) adjuvant. Sean M. Sullivan, Ph.D., Vical's Executive Director of Pharmaceutical Sciences, is presenting data at the IIRUS...
|
|
Detailed Data From Vical's TransVax(TM) CMV Vaccine Phase 2 Trial Presented in Late-Breaker Session at ICAAC
Sep 14, 2009
|
9.9 KB |
| |
SAN DIEGO, Sept. 14, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that detailed results from a four-month interim analysis in an ongoing Phase 2 trial of the company's TransVax(TM) therapeutic cytomegalovirus (CMV) DNA vaccine were presented yesterday in a late-breaker session at the Interscience Conference on Antimicro...
|
|
Vical Pandemic Influenza Vaccine Demonstrates Cross-reactivity Against California, Texas and Mexico H1N1 Strains
Sep 10, 2009
|
9.3 KB |
| |
SAN DIEGO, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's DNA vaccine against A/H1N1 pandemic influenza (swine flu) has demonstrated robust immune responses in 100% of vaccinated animals against virus strains isolated from recent outbreaks in three distinct geographic locations -- California, ...
|
|
Vical Receives $2.5 Million Payment for Funding of Allovectin-7(r) Phase 3 Trial
Sep 8, 2009
|
8.3 KB |
| |
SAN DIEGO, Sept. 8, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the receipt from AnGes MG, Inc., of a $2.5 million installment payment for the company's ongoing Allovectin-7(r) Phase 3 metastatic melanoma trial. Through a series of cash payments and equity investments under a previously announced collaborative agreemen...
|
|
Vical Receives Broad U.S. Patent for Vaxfectin(R)-Formulated DNA Vaccines for Influenza; Coverage Includes All Seasonal and Pandemic Strains
Sep 3, 2009
|
8.9 KB |
| |
SAN DIEGO, Sept. 3, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,582,613 covering Vaxfectin(R)-formulated DNA vaccines for influenza. The patent provides broad coverage for any circulating or potential influenza viruses, including both seasonal and pandemic strains.
The company is cu...
|
|
Vical to Present At Upcoming Investor Conferences
Sep 2, 2009
|
7.2 KB |
| |
SAN DIEGO, Sept. 2, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at four upcoming investor conferences:
* Thomas Weisel Partners Heal...
|
|
Vical Reports Second Quarter 2009 Financial Results and Updates Progress in Key Programs
Aug 6, 2009
|
15.5 KB |
| |
SAN DIEGO, Aug. 6, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the quarter ended June 30, 2009. Revenues increased to $4.0 million for the second quarter of 2009 from $2.5 million for the second quarter of 2008, primarily as a result of a $1.5 million milestone payment from Merck & Co., Inc., based...
|
|
Vical and Teva Establish Sales and Marketing Agreement for Allovectin-7(r) in Israel
Aug 3, 2009
|
10.4 KB |
| |
SAN DIEGO, Aug. 3, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced an exclusive agreement with Abic Marketing Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., for sales and marketing of the company's Allovectin-7(r) immunotherapeutic product candidate in Israel. Teva has agreed to pay Vical upfront and milesto...
|
|
Vical Announces News Release and Conference Call Schedule For Second Quarter 2009 Financial Results
Jul 30, 2009
|
7.6 KB |
| |
SAN DIEGO, July 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and six months ended June 30, 2009, before the opening of trading on Thursday, August 6, and conduct a conference call and webcast to discuss the financial results and provide a company up...
|
|
Federated Kaufmann Funds to Invest $10 Million in Vical
Jul 28, 2009
|
7.3 KB |
| |
SAN DIEGO, July 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has received a commitment from the Federated Kaufmann Funds to purchase $10.0 million of its common stock in a registered direct offering. Vical will sell approximately 2.8 million shares at a price of $3.63 per share, the Nasdaq closing consolidat...
|
|
Vical TransVax(tm) CMV Vaccine Achieves Promising Interim Clinical Results in Phase 2 Trial
Jul 8, 2009
|
11.7 KB |
| |
SAN DIEGO, July 8, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that its TransVax(tm) therapeutic DNA cytomegalovirus (CMV) vaccine provided promising results compared with placebo across a broad range of clinical efficacy endpoints at the four-month interim analysis in an ongoing Phase 2 trial. The trial is evaluating ...
|
|
Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax(tm) CMV Vaccine Phase 2 Interim Efficacy Results
Jul 7, 2009
|
7.7 KB |
| |
SAN DIEGO, July 7, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report tomorrow the interim efficacy results from the company's Phase 2 trial evaluating the potential for its TransVax(tm) therapeutic DNA vaccine to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem cell...
|
|
Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response
Jun 30, 2009
|
8.9 KB |
| |
SAN DIEGO, June 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 7...
|
|
Vical Receives Milestone Payment From Merck & Co., Inc.
Jun 22, 2009
|
7.1 KB |
| |
SAN DIEGO, June 22, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the receipt of a $1.5 million milestone payment from Merck & Co., Inc. based on Merck's ongoing Phase I clinical-stage development of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on Vical's DNA gene delivery technolo...
|
|
Vical Advances RapidResponse(tm) DNA Vaccine Platform Under $6 Million Grant From NIH
Jun 18, 2009
|
10.1 KB |
| |
SAN DIEGO, June 18, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company has successfully completed second-year milestones under a three-year, $6.0 million grant awarded in 2007, and is advancing with the development of a DNA vaccine manufacturing process with the potential to produce several million doses of v...
|
|
Vical Announces Issuance of U.S. Patent for Universal Influenza Vaccine Approach
Jun 3, 2009
|
8.5 KB |
| |
SAN DIEGO, June 3, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,537,768 covering the use of influenza virus gene sequences in a universal vaccine that could provide protection against circulating seasonal strains as well as emerging pandemic strains of influenza viruses.
Vical has pa...
|
|
Vical to Present At Upcoming Investor Conferences
Jun 1, 2009
|
7.0 KB |
| |
SAN DIEGO, June 1, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at two upcoming investor conferences:
-- The Noble Financial Group Fi...
|
|
Vical to Present Update On Pandemic Influenza Vaccine Program and Overview of Pivotal Phase 3 Melanoma Trial At ASGT Conference
May 27, 2009
|
7.0 KB |
| |
SAN DIEGO, May 27, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will be presenting at a series of upcoming conferences. At the annual meeting of the American Society of Gene Therapy (San Diego, CA, May 27 - 30):
* Vical's Executive Vice President of Product Development, Alain P.
Rolland, Pharm...
|
|
Vical Receives Additional Commitment in Registered Direct Offering
May 26, 2009
|
7.7 KB |
| |
SAN DIEGO, May 26, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has received a commitment from an additional institutional investor, Special Situations Funds, to purchase approximately $4.6 million of securities on the same terms specified in the registered direct offering announced on May 22. Under the terms of...
|
|
Vical to Raise $15.4 Million in Registered Direct Offering
May 22, 2009
|
7.7 KB |
| |
SAN DIEGO, May 22, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has received commitments from two institutional investors, including Federated Kaufmann Fund, to purchase approximately $15.4 million of securities in a registered direct offering. Vical expects to receive net proceeds of approximately $14.6 million...
|
|
Vical Advances H1N1 Pandemic Influenza (Swine Flu) Vaccine
May 21, 2009
|
8.6 KB |
| |
SAN DIEGO, May 21, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that in the two weeks since launching its program to develop a vaccine against H1N1 influenza (swine flu), the company has completed development of a prototype H1 vaccine, produced an initial supply of research-grade material, and initiated immunogenicity t...
|
|
Vical to Open NASDAQ Stock Market
May 20, 2009
|
7.4 KB |
| |
SAN DIEGO, May 20, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will preside over The NASDAQ Stock Market Opening Bell ceremony at 9:30 a.m. EDT on Thursday, May 21. The event will be accessible via live webcast at http://www.nasdaq.com/reference...
|
|
Vical Receives $2.5 Million Payment for Continued Funding of Allovectin-7(r) Phase 3 Trial
May 18, 2009
|
8.9 KB |
| |
SAN DIEGO, May 18, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the receipt of a $2.5 million cash payment from AnGes MG, Inc., related to continued progress in the company's ongoing Allovectin-7(r) Phase 3 metastatic melanoma trial. Through a series of cash payments and equity investments under a previously announced c...
|
|
Vical Grants Johns Hopkins Bloomberg School of Public Health Academic License for Core Technology
May 14, 2009
|
7.6 KB |
| |
SAN DIEGO, May 14, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company has granted a non-exclusive, academic license for its broad DNA delivery technology patent estate to the Johns Hopkins Bloomberg School of Public Health. The company had previously announced the grant of academic licenses on the same terms ...
|
|
Vical Reports First Quarter 2009 Financial Results and Progress in Key Programs
May 7, 2009
|
14.5 KB |
| |
SAN DIEGO, May 7, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the quarter ended March 31, 2009. Revenues increased to $2.3 million for the first quarter of 2009 from $1.9 million for the first quarter of 2008, primarily as a result of funding of Allovectin-7(r) Phase 3 trial activities under the co...
|
|
Vical and U.S. Navy to Expedite Development of H1N1 Pandemic Influenza (Swine Flu) Vaccine
May 6, 2009
|
8.5 KB |
| |
SAN DIEGO, May 6, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company has entered into a Cooperative Research and Development Agreement (CRADA(i)) with the U.S. Naval Medical Research Center (NMRC), a biomedical research organization within the U.S. Navy, for the expedited development of a vaccine against the ...
|
|
Vical Announces News Release and Conference Call Schedule for First Quarter 2009 Financial Results
Apr 30, 2009
|
7.6 KB |
| |
SAN DIEGO, April 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2009, before the opening of trading on Thursday, May 7, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eas...
|
|
Vical Updates Lead Vaccine Programs At NFID Vaccine Research Conference and Addresses Potential Response to H1N1 Swine Influenza Outbreak
Apr 28, 2009
|
12.1 KB |
| |
BALTIMORE, April 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's Vice President of Vaccine Research, Larry R. Smith, Ph.D., is presenting updates on the company's pandemic influenza and cytomegalovirus (CMV) vaccine programs at the 12th Annual Conference on Vaccine Research sponsored by the National ...
|
|
Vical Reports Publication of Key Research Findings for Immunotherapeutic Herpes Vaccine
Apr 23, 2009
|
10.1 KB |
| |
SAN DIEGO, April 23, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the publication in the May 1 issue of the Journal of General Virology(1) of data from preclinical studies identifying potential targets for development of a herpes simplex virus type 2 (HSV-2) vaccine. HSV-2 is a sexually transmitted virus which is the le...
|
|
Vical's Vaxfectin(r) Adjuvant Named One of 100 Great Investigational Drugs in Eighth Annual Ranking by Editors of R&D Directions
Apr 9, 2009
|
9.5 KB |
| |
SAN DIEGO, April 9, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that its patented adjuvant, Vaxfectin(r), was selected by R&D Directions editors for the magazine's 8th annual list of "100 Great Investigational Drugs" featured as the cover article in the March 2009 issue. Editors selected compounds that "show particular...
|
|
Vical's Allovectin-7(r) Phase 3 Trial Receives Positive Review From Safety Monitoring Board
Mar 24, 2009
|
10.4 KB |
| |
SAN DIEGO, March 24, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 AIMM trial of Allovectin-7(r) in patients with metastatic melanoma has completed the trial's second scheduled safety analysis and recommended that the trial continue per the proto...
|
|
Vical to Present At Upcoming Investor Conferences
Mar 5, 2009
|
6.9 KB |
| |
SAN DIEGO, March 5, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of the company's technologies, development programs, and strategic partnerships at two upcoming investor conferences.
* Vical's President and Chief Executive Officer, Vijay B. Samant,
will present at the...
|
|
Vical Reports 2008 Financial Results and Progress in Product Development Programs
Feb 17, 2009
|
14.9 KB |
| |
SAN DIEGO, Feb. 17, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2008. Vical had cash and investments of approximately $42 million at year-end 2008, including approximately $5 million invested in long-term auction rate securities.
Revenues for 2008 were $8.0 million, c...
|
|
Vical Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting
Feb 13, 2009
|
9.4 KB |
| |
GENEVA, Feb. 13, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today presented to the world's leading pandemic influenza vaccine experts a summary of complete results from the company's successful Phase 1 trial and future goals for its pandemic influenza DNA vaccine program. Larry R. Smith, Ph.D., Vical's Vice President of Vaccine Resea...
|
|
Vical Receives $2.3 Million Payment for Continued Funding of Allovectin-7(r) Phase 3 Trial
Feb 11, 2009
|
9.0 KB |
| |
SAN DIEGO, Feb. 11, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the receipt of a $2.3 million cash payment from AnGes MG, Inc., related to continued progress in the company's ongoing Allovectin-7(r) Phase 3 metastatic melanoma trial. Through a series of cash payments and equity investments under a previously announced ...
|
|
Vical Announces News Release and Conference Call Schedule for 2008 Financial Results
Feb 10, 2009
|
7.6 KB |
| |
SAN DIEGO, Feb. 10, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and twelve months ended December 31, 2008, before the opening of trading on Tuesday, February 17, and conduct a conference call and webcast to discuss the financial results and provide a c...
|
|
Vical Announces Issuance of U.S. Patent No. 7,470,675 for Composition, Delivery and Use of Gene-Based Interferon-Omega
Jan 14, 2009
|
8.3 KB |
| |
SAN DIEGO, Jan. 14, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,470,675 covering the composition, delivery and use of gene-based interferon-omega. Interferon-omega is part of the interferon family of proteins which are naturally produced by the immune system. Several interferons hav...
|
|
Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
Dec 11, 2008
|
11.6 KB |
| |
LAS VEGAS, Dec 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Vical Incorporated (Nasdaq: VICL) today announced that the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain i...
|
|
SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
Dec 9, 2008
|
10.7 KB |
| |
SAN DIEGO, Dec 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Vical Incorporated
(Nasdaq: VICL) today announced that results from a Phase I clinical trial of a
DNA vaccine for severe acute respiratory syndrome (SARS), conducted by the
National Institutes of Health (NIH) and published in the November 25 issue of
Vaccine(1), demonstra...
|
|
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
Dec 3, 2008
|
12.5 KB |
| |
SAN DIEGO, Dec 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Vical Incorporated
(Nasdaq: VICL) today announced an exclusive, binding letter of intent with EIP
Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and marketing of the company's
Allovectin-7(R) immunotherapeutic product candidate in Turkey and the Turkish
Republic of Northe...
|
|
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
Dec 1, 2008
|
7.7 KB |
| |
SAN DIEGO, Dec 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Vical Incorporated (Nasdaq: VICL) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on ...
|
|
Vical Announces Strategic Restructuring and Staff Reduction
Nov 21, 2008
|
8.0 KB |
| |
SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced a strategic restructuring including a staff
reduction of 29 employees, approximately 20% of the company's total workforce,
and accelerated closure of a research facility. Following the restructuring,
the company will have approximately 120 employees a...
|
|
Vical Executive Alain Rolland Named AAPS Fellow
Nov 17, 2008
|
9.4 KB |
| |
ATLANTA, Nov. 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq:
VICL) today announced that Alain P. Rolland, Pharm.D., Ph.D., the company's
Senior Vice President, Product Development, was named a Fellow of the American
Association of Pharmaceutical Scientists (AAPS). The AAPS Fellow designation
is granted each year to select individuals ...
|
|
Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
Nov 12, 2008
|
10.2 KB |
| |
SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq:
VICL) announced today that the company has completed enrollment of subjects in
a Phase 2 trial of its therapeutic DNA vaccine designed to prevent
cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem cell
transplant recipients. An interim analysis of immu...
|
|
U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
Nov 6, 2008
|
11.5 KB |
| |
SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that the Naval Medical Research Center (NMRC)
plans to conduct preclinical and Phase 1 evaluation of a dengue DNA vaccine
formulated with the company's Vaxfectin® adjuvant and delivered with the
Biojector...
|
|
Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Program
Nov 5, 2008
|
13.3 KB |
| |
SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today reported financial results for the quarter ended
September 30, 2008. Revenues for the third quarter of 2008 were $0.8 million,
compared with revenues of $0.4 million for the third quarter of 2007. The net
loss for the third quarter of 2008 was $9.8 million or $0...
|
|
Vical to Present at Upcoming Investor Conferences
Nov 4, 2008
|
6.6 KB |
| |
NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- The Vical Incorporated (Nasdaq:
VICL) presentation at the Rodman & Renshaw Annual Global Investor Conference
at 4:05 p.m. Eastern Time on Tuesday, November 11, will be available by live
and archived webcast through the Events page at www.vical.com. Vical's
presentation at the Lazard Capital Markets...
|
|
Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
Oct 29, 2008
|
7.9 KB |
| |
SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq:
VICL) today announced that the company will report financial results for the
three months and nine months ended September 30, 2008, before the opening of
trading on Wednesday, November 5, and conduct a conference call and webcast to
discuss the financial results and provid...
|
|
Vical to Present at Upcoming Investor Conferences
Oct 23, 2008
|
6.4 KB |
| |
SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) will be presenting an overview of the company's independent and
collaborative development programs at the BIOCOM Investor Conference in San
Diego on Tuesday, October 28, and at the BIO Investor Forum in San Francisco
on Wednesday, October 29.
About Vical...
|
|
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Oct 8, 2008
|
10.9 KB |
| |
LYON, France, Oct. 8 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL) today is presenting expanded clinical data and new nonclinical data demonstrating that the company's Vaxfectin® adjuvant may be broadly applicable in DNA- and protein-based infectious disease vaccines and peptide-based cancer vaccines. Al...
|
|
Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
Oct 7, 2008
|
7.1 KB |
| |
SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) and AnGes MG, Inc., have signed a non-binding Letter of Intent
indicating their mutual interest to license the development and marketing
rights for Vical's pandemic influenza DNA vaccines in Japan to AnGes. AnGes
plans to conduct due diligence on the pandemic influenz...
|
|
Vical to Present at UBS Global Life Sciences Conference
Sep 15, 2008
|
6.5 KB |
| |
NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- The Vical Incorporated
(Nasdaq: VICL) presentation at the UBS Global Life Sciences Conference on
Monday, September 22, at 1 p.m. Eastern Daylight Time, will be available by
live and archived webcast through the Events page at http://www.vical.com.
About Vical
Vical researches a...
|
|
Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants
Aug 21, 2008
|
11.1 KB |
| |
SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that results from nonhuman primate studies of a
Vaxfectin®-formulated DNA vaccine for measles, published in the August issue
of Clinical and Vaccine Immunology(1), offer a promising approach to the
development of ...
|
|
Karolinska Institutet to Test Vical’s Vaxfectin® Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
Aug 19, 2008
|
10.9 KB |
| |
SAN DIEGO—August 19, 2008—Vical Incorporated (Nasdaq:VICL) today announced a research collaboration with the Karolinska Institutet (KI), a leading European medical university, and the Swedish Institute for Infectious Disease Control (SMI), a governmental expert agency, to evaluate Vical’s Vaxfectin® adjuvant with the Bioje...
|
|
Vical Reports Second Quarter and First Six Months 2008 Financial Results and Highlights in Product Development Programs
Aug 5, 2008
|
13.5 KB |
| |
SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today reported financial results for the quarter and six months
ended June 30, 2008. Revenues for the second quarter of 2008 were
$2.5 million, compared with revenues of $3.1 million for the second quarter of
2007. The net loss for the second quarter of 2008 was $8.5 ...
|
|
Vical Announces News Release and Conference Call Schedule for Second Quarter 2008 Financial Results
Jul 29, 2008
|
8.4 KB |
| |
SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that the company will report financial results
for the three months and six months ended June 30, 2008, before the opening of
trading on Tuesday, August 5, and conduct a conference call and webcast to
discuss the financial results and provide a compan...
|
|
Vical Receives $1 Million Milestone Payment From AnGes MG for Angiogenesis Program
Jul 22, 2008
|
7.9 KB |
| |
SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced the receipt of a $1.0 million cash payment from
its partner, AnGes MG, Inc., reflecting continued progress of its
Collategene™ angiogenesis program. Vical received an initial upfront
payment of $1.0 million under...
|
|
Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
Jul 17, 2008
|
12.5 KB |
| |
SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced a breakthrough with preliminary clinical trial
data demonstrating that DNA vaccines can safely achieve significant immune
responses against H5N1 pandemic influenza in humans. DNA vaccines are
fundamentally different from conventional vaccines because ...
|
|
Vical to Present Phase 1 Data for Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines
Jul 14, 2008
|
8.9 KB |
| |
SAN DIEGO, July 14 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced the scheduled presentation of preliminary human
safety and immunogenicity data from a Phase 1 trial of the company's
Vaxfectin®-formulated H5N1 pandemic influenza DNA vaccines on Thursday, July
17, at the IBC Life...
|
|
Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Jun 25, 2008
|
10.4 KB |
| |
SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that the company has successfully completed
first-year milestones under a three-year, $6.0 million grant awarded in 2007,
and is advancing with the development of a DNA vaccine manufacturing process
with the potential to produce several million doses ...
|
|
Vical Pandemic Influenza Vaccines Provide Complete Protection in Animal Studies; The Journal of Infectious Diseases Publishes H5N1 Challenge Data
Jun 16, 2008
|
9.3 KB |
| |
SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) announced today the publication of results demonstrating that
pandemic influenza DNA vaccines formulated with the company's patented
Vaxfectin® adjuvant provided complete protection of mice and ferrets against
lethal challenge wi...
|
|
Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
Jun 12, 2008
|
10.5 KB |
| |
SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced the receipt of $6.3 million of cash payments
and equity investments from AnGes MG, Inc., under a previously announced
collaborative agreement for continued funding of the company's ongoing
Allovectin-7® Phase 3 me...
|
|
Promise of Vical's CMV Vaccine Noted by Independent Experts
Jun 5, 2008
|
10.0 KB |
| |
SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- In an editorial commentary(1)
in the current issue of The Journal of Infectious Diseases (JID), independent
experts on cytomegalovirus (CMV) said the vaccine under development by Vical
Incorporated (Nasdaq: VICL), at the optimal dose and regimen tested, "holds
promise" based on its ability to elicit p...
|
|
Vical to Present at Needham & Company Biotechnology and Medical Technology Conference
Jun 4, 2008
|
6.5 KB |
| |
NEW YORK, June 4 /PRNewswire-FirstCall/ -- The Vical Incorporated
(Nasdaq: VICL) presentation at the Seventh Annual Needham & Company
Biotechnology and Medical Technology Conference on Thursday, June 12, at 10
a.m. Eastern Daylight Time, will be available by live and archived webcast
through the Events page at http://www.vical.com.
...
|
|
Vical to Present at Upcoming Investor Conferences
May 12, 2008
|
6.8 KB |
| |
SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that Vical's President and Chief Executive
Officer, Vijay B. Samant, will provide an overview of the company's
technologies, development programs, and strategic partnerships at three
upcoming investor conferences:
* Bank of America 2008...
|
|
Vical Reports First Quarter 2008 Financial Results and Updates Key Development Programs
May 8, 2008
|
12.8 KB |
| |
SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today reported financial results for the quarter ended
March 31, 2008. Revenues for the first quarter of 2008 were $1.9 million,
compared with revenues of $1.3 million for the first quarter of 2007. The net
losses for the first quarters of both 2008 and 2007 were $9.6 ...
|
|
Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
May 1, 2008
|
7.4 KB |
| |
SAN DIEGO, May 1 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that the company will report financial results
for the quarter ended March 31, 2008, before the opening of trading on
Thursday, May 8, and conduct a conference call and webcast to discuss the
financial results and provide a company update at noon Easter...
|
|
Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
Apr 23, 2008
|
11.4 KB |
| |
SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced the release to television news stations
nationwide of an independently produced video report featuring metastatic
melanoma patients treated with the company's Allovectin-7® immunotherapeutic
product candidate. Th...
|
|
Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
Apr 3, 2008
|
9.8 KB |
| |
SAN DIEGO, April 3, 2008 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that it has been awarded a two-year,
$2.0 million Phase II Small Business Technology Transfer (STTR) grant from the
U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the
National Institutes of Health (NIH), an agency of the U...
|
|
Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
Mar 28, 2008
|
9.9 KB |
| |
SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced the company's licensee, AnGes MG, Inc.,
reported submission on March 27, 2008, of a New Drug Application (NDA) to the
Japanese Ministry of Health, Labor and Welfare for its angiogenesis product
candidate, Collategene, for treatment of critical limb i...
|
|
Vical to Present at Cowen and Company Health Care Conference
Mar 12, 2008
|
6.5 KB |
| |
BOSTON, March 12 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) announced today that the company will present an overview of
its product development programs on Monday, March 17, at the 28th Annual Cowen
and Company Health Care Conference (Boston -- March 17-20).
About Vical
Vical researches and develops biop...
|
|
Vical to Present at BIO and BVGH Global Health Partnering Event
Mar 4, 2008
|
7.3 KB |
| |
WASHINGTON, March 4 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that Vijay Samant, the company's President and
Chief Executive Officer, will participate in a roundtable discussion, "An
Industry Call to Action: Challenges and Opportunities for Engaging in Global
Health Product Development," and present an overview...
|
|
Vical Reports 2007 Financial Results and Progress in Product Development Programs
Feb 21, 2008
|
12.4 KB |
| |
SAN DIEGO, Feb. 21 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today reported financial results for the year ended
December 31, 2007. Vical had cash and investments of approximately $71 million
at year-end 2007, which is expected to be sufficient to fund operations at
least through 2009.
The reported net loss for 200...
|
|
Vical Announces News Release and Conference Call Schedule for 2007 Financial Results
Feb 14, 2008
|
7.3 KB |
| |
SAN DIEGO, Feb. 14 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that the company will report financial results
for the quarter and year ended December 31, 2007, before the opening of
trading on Thursday, February 21, and conduct a conference call and webcast to
discuss the financial results and provide a company u...
|
|
Vical to Present at BIO CEO and Investor Conference
Feb 5, 2008
|
6.6 KB |
| |
NEW YORK, Feb 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Vical Incorporated
(Nasdaq: VICL) today announced that Vijay Samant, the company's President and
Chief Executive Officer, will present a company overview at 3:30 p.m. EST on
Monday, February 11, at the Biotechnology Industry Organization (BIO) CEO and
Investor Conference (...
|
|
Vical Expands Portfolio of CMV Vaccine Technologies Through License Agreement With The Wistar Institute
Jan 22, 2008
|
10.7 KB |
| |
SAN DIEGO, Jan. 22 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced a license agreement with The Wistar Institute
granting Vical exclusive, worldwide rights to Wistar's Towne strain of
cytomegalovirus (CMV) and related technologies. Financial terms of the license
agreement were not disclosed.
The Towne str...
|
|
Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
Jan 17, 2008
|
7.8 KB |
| |
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced the receipt of a $2.1 million cash payment from
AnGes MG, Inc. for costs associated with the ongoing Allovectin-7®
Immunotherapeutic for Metastatic Melanoma (AIMM) Phase 3 trial.
AnGes is funding the Ph...
|
|
Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
Jan 7, 2008
|
7.5 KB |
| |
SAN FRANCISCO, Jan. 7 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that Vijay Samant, President and Chief
Executive Officer, will participate in a panel discussion on biodefense and
pandemic influenza Wednesday evening at the 26th Annual JPMorgan Healthcare
Conference (San Francisco, CA - January 7-10).
...
|
| Showing 1-121 of 121 |
Page: 1 |
|
|
